Ask AI
See Activity Collection
ProCE Banner Activity

InterACT ADC Treatment Optimization & Care Team Activation in PROC: Enhancing Multidisciplinary Implementation, Toxicity Mitigation, and Workflow Readiness in Community Practice

Slideset

Explore current evidence and emerging strategies for antibody–drug conjugates in patients with platinum-resistant ovarian cancer, including biomarker-guided use of FRα-directed and HER2-directed therapies and the evolving roles of investigational targets. Examine how biomarker results, prior treatment, rate of disease progression, comorbidities, baseline toxicity risk, patient goals, along with multidisciplinary workflows for treatment readiness and escalation of care.

Released: October 14, 2026

Continue Activity

Share

Faculty

Kathleen N. Moore

Kathleen N. Moore, MD, MS, FASCO

Deputy Director & Director of Phase 1 Research
Fred & Pamela Buffett Cancer Center
Omaha, Nebraska
Shannon N. Westin

Shannon N. Westin, MD, MPH, FASCO

Professor
Medical Director, Gynecologic Oncology Center
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with the National Ovarian Cancer Coalition.

ProCE Banner

Supporters

This activity is supported by an independent educational grant from Genmab.

Genmab

Target Audience

This activity is intended for multidisciplinary teams caring for patients with ovarian cancer, including oncologists, oncology nurses, APPs, pharmacists, infusion staff, care coordinators, patient navigators, and other HCPs responsible for treatment selection, ADC delivery, toxicity monitoring, care transitions, and patient/caregiver education.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply current guideline recommendations, recurrence biomarker testing results, prior treatment history, disease tempo, comorbidities, baseline toxicity risk, and patient goals to identify appropriate candidates for ADC therapy, non-ADC systemic therapy, clinical trial referral, or supportive-care integration in PROC

  • Differentiate currently available and emerging ADC strategies in recurrent ovarian cancer by target, payload, evidence base, biomarker requirement, anticipated toxicity profile, dosing considerations, and role in treatment sequencing

  • Select evidence-aligned baseline assessments, prophylactic measures, monitoring intervals, dose-modification steps, and escalation pathways for ADC-associated ocular toxicity, neuropathy, interstitial lung involvement/ILD-pneumonitis, cytopenias, gastrointestinal toxicity, fatigue, and infusion-related events

  • Implement a multidisciplinary ADC Care Pathway that assigns team roles for biomarker ordering and tracking, treatment readiness, patient/caregiver education, symptom triage, specialty referral, dose decision-making, documentation, and follow-up across community practice

Financial Disclosures

Primary Author

Kathleen N. Moore, MD, MS, FASCO: consultant/advisor/speaker: Aadi, AbbVie, AstraZeneca, Corcept, Daiichi Sankyo, Duality, Genmab, Gilead, GSK, ImmunoGen, Incyte, Janssen, Lilly, Merck, Pfizer, Regeneron, Schrödinger, Takeda, Tubulis, Verastem, Whitehawk, Zymeworks.

Shannon N. Westin, MD, MPH, FASCO: researcher: AstraZeneca, Avenge Bio, Bayer, BioPath, Clovis/Pharma&, Daiichi Sankyo, Genmab, GSK, Jazz, Loxo, Mereo, Novartis, Nuvectis, Pfizer, Roche/Genentech, Verastem, Zentalis; consultant/advisor/speaker: AbbVie, AstraZeneca, Bayer, Caris, Clovis/Pharma&, Corcept, Daiichi Sankyo, Eisai, Faeth, Genmab, Gilead, GSK, Immunocore, ImmunoGen, Incyte, Lilly, Loxo, Merck, Mereo, NGM Bio, Nuvectis, Ottimo, Pfizer, PMV Pharma, Roche/Genentech, Seagen, Verastem, Zentalis, ZielBio.